Clinical trial
Combination Chemotherapy Plus Low-Dose Radiation Therapy in Treating Patients…
NCT00026208 · Stanford University, Other · Completed
Key facts
| NCT number | NCT00026208 |
|---|---|
| Title | Combination Chemotherapy Plus Low-Dose Radiation Therapy in Treating Patients With Stage I or Stage IIA Hodgkin's Lymphoma |
| Official title | Risk-Adapted Stanford V-C With Radiotherapy for Clinical Stage I and IIA Favorable Hodgkin's Disease: The G5 Study |
| Lead sponsor | Stanford University, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lymphoma, Hodgkin Disease, Lymphoma: Hodgkin |
| Intervention type | Drug, Radiation |
| Interventions | Vincristine, Cyclophosphamide, Doxorubicin, Prednisone, Bleomycin, Etoposide, Low-dose radiotherapy (RT) |
| Enrollment | 76 |
| Start date | Jun 1, 2001 |
| Primary completion | Apr 26, 2013 |
| Completion | Feb 13, 2017 |
| First posted | Jan 27, 2003 |
| Last update posted | Jul 24, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: